Estrella Immunopharma (NASDAQ:ESLA) Stock Price Crosses Above 50 Day Moving Average – Time to Sell?

Estrella Immunopharma, Inc. (NASDAQ:ESLA) shares crossed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $0.55 and traded as high as $0.7699. Estrella Immunopharma shares last traded at $0.7472, with a volume of 3,907,990 shares traded.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, October 28th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Estrella Immunopharma currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Estrella Immunopharma Stock Performance

The stock has a market cap of $32.50 million, a price-to-earnings ratio of -3.11 and a beta of 0.88. The company has a 50 day moving average of $0.55 and a 200-day moving average of $0.97.

Estrella Immunopharma (NASDAQ:ESLA) last released its earnings results on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.04. On average, research analysts anticipate that Estrella Immunopharma, Inc. will post -0.25 EPS for the current year.

Hedge Funds Weigh In On Estrella Immunopharma

An institutional investor recently bought a new stake in Estrella Immunopharma stock. BlackRock Inc. acquired a new position in shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 52,033 shares of the company’s stock, valued at approximately $54,000. BlackRock Inc. owned about 0.12% of Estrella Immunopharma as of its most recent filing with the SEC. 0.35% of the stock is currently owned by hedge funds and other institutional investors.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc. (NASDAQ: ESLA) is a clinical-stage biopharmaceutical company focused on developing cellular immunotherapies for cancer and other serious diseases. The company’s work centers on genetically engineered T-cell therapies designed to recognize and destroy target cells. Estrella’s lead program is EB103, a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy being developed for the treatment of certain B-cell malignancies. The company has described EB103 as being based on its ARTEMIS platform, which is intended to support targeted immune-cell activity while addressing some limitations associated with conventional CAR-T therapies.